Marker Therapeutics (NASDAQ:MRKR) Shares Down 2.6%
Marker Therapeutics (NASDAQ:MRKR) Shares Down 2.6%
Marker Therapeutics, Inc. (NASDAQ:MRKR – Get Rating)'s stock price fell 2.6% on Tuesday . The company traded as low as $0.28 and last traded at $0.29. 134,907 shares traded hands during mid-day trading, a decline of 85% from the average session volume of 872,656 shares. The stock had previously closed at $0.29.
納斯達克股價週二下跌2.6%,盤中一度跌至0.28美元,最新報0.29美元。午盤,134,907股股票易手,較872,656股的平均成交量下跌85%。此前該股收盤價為0.29美元。
Marker Therapeutics Trading Down 2.6 %
標記物治療公司股價下跌2.6%
The stock has a 50 day simple moving average of $0.37 and a 200-day simple moving average of $0.35. The firm has a market capitalization of $23.83 million, a P/E ratio of -0.66 and a beta of 1.03.
該股的50日簡單移動均線切入位為0.37美元,200日簡單移動均線切入位為0.35美元。該公司的市值為2383萬美元,本益比為-0.66,貝塔係數為1.03。
Institutional Investors Weigh In On Marker Therapeutics
機構投資者對Marker Treeutics的看法
Large investors have recently made changes to their positions in the company. Raymond James & Associates bought a new stake in shares of Marker Therapeutics during the 3rd quarter valued at about $35,000. Matrix Asset Advisors Inc. NY grew its stake in shares of Marker Therapeutics by 66.7% during the 2nd quarter. Matrix Asset Advisors Inc. NY now owns 250,000 shares of the company's stock valued at $83,000 after acquiring an additional 100,000 shares during the period. Finally, AR Asset Management Inc. grew its stake in shares of Marker Therapeutics by 290.2% during the 1st quarter. AR Asset Management Inc. now owns 279,000 shares of the company's stock valued at $123,000 after acquiring an additional 207,500 shares during the period. 26.62% of the stock is currently owned by institutional investors.
大型投資者最近對他們在該公司的頭寸進行了調整。Raymond James&Associates在第三季度購買了Marker Treateutics的新股份,價值約3.5萬美元。第二季度,Matrix Asset Advisors Inc.NY在Marker Treeutics的持股增加了66.7%。Matrix Asset Advisors Inc.NY在此期間增持了10萬股,目前持有該公司250,000股股票,價值83,000美元。最後,AR資產管理公司在第一季度增持了290.2%的梅克爾治療公司的股份。AR Asset Management Inc.在此期間增持了207,500股,目前擁有27.9萬股該公司股票,價值12.3萬美元。26.62%的股票目前由機構投資者持有。
Marker Therapeutics Company Profile
標記物治療公司簡介
Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens.
Mark Treateutics,Inc.是一家臨床階段的免疫腫瘤學公司,在美國從事各種基於T細胞的免疫療法和基於多肽的疫苗的開發和商業化,用於治療血液系統惡性腫瘤和實體腫瘤適應症。它的多TAA特異性T細胞技術是基於製造非工程腫瘤特異性T細胞,這種T細胞識別多種腫瘤相關抗原,並殺死表達腫瘤相關抗原的腫瘤細胞。
Further Reading
進一步閱讀
- Get a free copy of the StockNews.com research report on Marker Therapeutics (MRKR)
- Ulta Issues A Beautiful FY Outlook, But Is the Stock A Buy Now?
- Should The Bancorp Make Your Small-Cap Watchlist for 2023?
- 3 Consumer Cyclical Stocks With Good Momentum
- Could Pinduoduo Be the Best Chinese Stock to Own?
- 3 Big Box Retail Bets for the Holidays
- 免費獲取StockNews.com關於標記物治療的研究報告(MRKR)
- Ulta發佈美好的財年前景,但這只股票現在是買入的嗎?
- Bancorp應該入選2023年小盤股觀察名單嗎?
- 3勢頭良好的消費週期股
- 拼多多可能是最值得持有的中國股票嗎?
- 節假日的三大零售賭注
Receive News & Ratings for Marker Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marker Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Marker Treateutics Daily》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Marker Treateutics和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。